tirzepatide being discontinued Causes and consequences of discontinuation of GLP1RAs or FDA says years-long tirzepatide shortage

Low Starting Amount Amount per injection: 1.0 mg 3 units (0.03 mL) on a U-100 insulin syringe Frequency: Once daily, under the skin (MonFri, weekends off) Cycle length: 812 weeks, then 24 weeks off Sources: [1] Regenerative and protective actions of the GHK-Cu peptide in the light of the new gene data NIH / PMC

Soon, the FDA will remove these peptides from the list

Here, again, your prescriber or doctor can likely help.

Neurosci Lett (1998) 249(23):10710

As more take these drugs, providers will have to correlate skincare and treatment plans to shifting facial volume and skin quality

GHK-Cu is supplied as a research-grade injectable reference compound